SGLT2 inhibitors improve survival over DPP4i in patients with cirrhosis and diabetes: Study

Written By : Medha Baranwal |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2021-07-20T11:45:06+05:30 | Updated On 20 July 2021 2:56 PM IST

Patients with cirrhosis needing additional pharmacotherapy for diabetes beyond metformin experience increased survival with SGLT2i in relation to DPP4i.

USA: SGLT2 inhibitors versus DPP4 inhibitors may improve survival in cirrhosis patients who require additional pharmacotherapy for diabetes beyond metformin, reveal results from a recent study in the journal Diabetes, Obesity and Metabolism.

Sodium-glucose cotransporter 2 inhibitors may have favorable metabolic and neurohumoral effects in chronic liver disease patients. However, studies examining SGLT2 inhibitors in this population are limited only to patients with non-alcoholic fatty liver disease (NAFLD) and have focused on surrogate biomarkers. Considering this, Saad Saffo, Yale School of Medicine, New Haven, Connecticut, and colleagues aimed to evaluate if SGLT2i can reduce the risk of death and ascites over a period of 36 months in patients with diabetes and cirrhosis.

Also Read: SGLT2 inhibitors cause double weight loss than GLP-1 receptor agonists in diabetics: Study

For this purpose, the researchers used electronic health data from Veterans Affairs hospitals in the United States. Following this, they conducted a propensity-score matched intention-to-treat analysis among veterans on metformin who subsequently received either SGLT2i or dipeptidyl peptidase-4 inhibitors (DPP4i).

Upon analysis, they found that among 423 matched pairs (846 total patients), there was no significant difference in the risk for ascites (HR 0.68 for SGLT2i) but SGLT2i users had a reduced risk for death (aHR 0.33).

The findings showed that in comparison to DPP4i, SGLT2i may improve survival for patients with cirrhosis who require additional pharmacotherapy for DM beyond metformin, however, there is a need for confirmatory studies, concluded the authors.

Also Read: High blood sugar tied to progression of cirrhosis in chronic hepatitis C: Study

Reference:

The study titled, "Impact of SGLT2 inhibitors in comparison to DPP4 inhibitors on ascites and death in veterans with cirrhosis on metformin," is published in the journal Diabetes, Obesity and Metabolism.

DOI: https://dom-pubs.onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14488

Diabetes Obesity and MetabolismcirrhosisDPP4 inhibitorsdiabetesSGLT2 inhibitorsmetforminsodium-glucose transporter 2 inhibitors

Source : Diabetes, Obesity and Metabolism

Medha Baranwal

MSc. Biotechnology

Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751